A phase 3 Study of ensitrelvir in japanese participants aged 6–11 years with SARS-CoV-2 infection
Clicks: 2
ID: 325570
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #39 of 40 articles by views in journal of the pediatric infectious diseases society
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Children aged <12 years with COVID-19 have limited treatment options; currently approved oral antivirals are restricted by age or bodyweight. We evaluated the safety and plasma concentration-time profiles and exploratory efficacy of ensitrelvir, a once-daily oral 3C-like protease inhibitor, in children with mild-to-moderate COVID-19 in Japan. METHODS: This phase 3, double-blind, placebo-controlled study randomized (2:1) participants aged 6 to <12 years presenting ≤72 h after COVID-19 onset to receive ensitrelvir (bodyweight-based dosing) or placebo once daily for 5 days. Primary endpoints were safety and PK. Secondary endpoints included change in viral RNA and time to resolution (TTR) of key COVID-19 symptoms (stuffy or runny nose and cough) plus fever. RESULTS: Of 117 randomized participants (median age 10 years), 78 received ensitrelvir and 39 received placebo. Ensitrelvir was well tolerated with no new safety concerns. Plasma concentration-time profiles were similar across bodyweight categories (20 to <30, 30 to <40, and ≥40 kg). Ensitrelvir reduced viral RNA vs placebo on Day 4, by approximately 1.0 log10 copies/mL (95% CI, -1.45 to -0.47). Median TTR of key COVID-19 symptoms was 140.5 h with ensitrelvir and 146.2 h with placebo (median difference -5.7 h [95% CI, -73.6 to 43.4 h]). CONCLUSIONS: In children aged 6 to <12 years with mild-to-moderate COVID-19 treated with ensitrelvir, we observed a favorable safety profile, adult-matched plasma concentration-time profile, and a greater reduction in viral RNA vs placebo. Ensitrelvir represents a potential treatment option for underserved pediatric patients with mild-to-moderate COVID-19. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCT2031230140 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT2031230140).
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (3 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7203779793
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Takashi Nakano, Hiroyuki Moriuchi, Isao Miyairi, Takumi Imamura, Maria Matsumoto, Yuko Tsuge, Takeki Uehara |
| Journal | journal of the pediatric infectious diseases society |
| Year | 2026 |
| DOI |
10.1093/jpids/piag071
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.